SEC EDGARSEP 101 min read$ATRC

Privitera Salvatore sold $201K of ATRC

Privitera Salvatore (Chief Technical Officer) sold 3,657 shares of AtriCure, Inc. (ATRC) at $55.00 ($0.20M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Privitera Salvatore

Published Sep 10, 2026, 1:18 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 10, 2026, 1:39 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ATRC

Neutral

medium confidence

Mentioned

$ATRC

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ATRCNeutralLow

Why it matters

The CTO's sale is modest and likely reflects personal financial planning rather than a change in company fundamentals.

Market read

Limited relevance; may cause slight short‑term price pressure but unlikely to affect longer‑term valuation.

What to watch

Potential upcoming regulatory or product news not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-10

Background

SEC Form 4 filing discloses insider transactions; required for transparency.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ATRCNeutralMedium confidence

Context

CTO Privitera Salvatore sold 3,657 shares for $201,135 via a 10b5-1 plan on 2026-09-08.

Expected impact

Minor downward pressure; unlikely to move price materially.

Evidence & confidence

The sale size is modest relative to holdings and market cap; market may view it as routine.

Market effects

Sector

None; the sale is company‑specific and does not affect the broader medical device sector.

Regional

None; limited to ATRC shareholders.

Global

None; no global ripple effect.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

Company
AtriCure, Inc.
Medical device manufacturer (ticker ATRC).
Executive
Privitera Salvatore
Chief Technical Officer of AtriCure.

Read at source ← All news

AUG 31

$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min

AUG 27

$ATRCMed

ATRC Maintained Overweight by Piper Sandler -- Price Target Rais

Piper Sandler maintained its Overweight rating for AtriCure (ATRC) and raised its price target from $50.00 to $60.00. The company's stock is currently trading at $48.16, which GuruFocus deems 21.6% overvalued. AtriCure has a GF Score of 79/100, indicating strong overall performance, but significant insider selling has occurred recently.

gurufocus.com2 min

AUG 27

$ATRCHighAI 8/10

Piper Sandler raises AtriCure stock price target on quality measure

Piper Sandler raised its price target for AtriCure (NASDAQ:ATRC) to $60, citing a new quality measure for atrial fibrillation treatment as a catalyst. The firm expects market penetration to increase, driving growth. AtriCure's Q2 2026 earnings beat estimates, but shares fell on cautious outlook. BTIG also raised its target to $55.

investing.com2 min

AUG 19

$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min

JUL 28

$ATRCMed

AtriCure, Inc. (ATRC) Beat Earnings Estimates. Here’s What Could Drive ATRC Stock Next

AtriCure (NASDAQ:ATRC) reported Q2 FY26 revenue of $153.6M and adjusted EPS of $0.18 on July 23, topping consensus by $1.79M and $0.16. Net income was $9M versus a $6.2M loss a year earlier. Gross margin rose to 77.2%. Management guided FY2026 revenue $602M-$610M and raised adjusted EBITDA to ~$85M-$89M.

yahoo.com7 min

JUL 23

$ATRCHigh

AtriCure, Inc. (ATRC): Results of Operations and Financial Condition

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi

SEC EDGAR 8-K3 min